Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 2
2010 pubmed 53 citations

Antimicrobial peptide response to blood translocation of bacterial DNA in Crohn's disease is affected by NOD2/CARD15 genotype.

Gutiérrez. Ana A; Holler. Ernst E; Zapater. Pedro P; Sempere. Laura L; Jover. Rodrigo R; Pérez-Mateo. Miguel M; Schoelmerich. Juergen J; Such. José J; Wiest. Reiner R; Francés. Rubén R

Key Findings

  • s patients and none of the healthy controls.",
  • ,

Practical Outcomes

  • For self‑experimenters, the findings suggest that LL‑37 could serve as a biomarker of gut barrier breach and bacterial translocation in Crohn's disease. However, the study does not provide dosing or supplementation guidance, so the immediate actionable step is to focus on strategies that support gut integrity and monitor inflammation rather than trying to boost LL‑37 directly.

Summary

In people with Crohn's disease, bits of bacterial DNA can leak into the blood, and this triggers the immune system to make more of the antimicrobial peptide LL‑37 (and β‑defensin 2). The rise is strongest in patients who have a normal NOD2 gene, while those with NOD2 mutations show a different regulation pattern. The study shows a link between gut‑derived bacterial DNA, immune peptides, and inflammation, but it doesn’t test any new treatments.

Abstract

Blood translocation of bacterial-DNA has been described in patients with Crohn's disease (CD). The host's immune cell types cooperate to respond against bacterial insults. Some antimicrobial peptides are inducible after culture with bacterial products and a linkage has been established between them and NOD2/CARD15. The aim was to test whether defensins and cathelicidin (LL-37) expression and NOD2/CARD15 mutations in blood neutrophils are related to molecular bacterial translocation events in CD patients. Fifty consecutively admitted CD patients and 15 healthy controls were included. Clinical and analytical characteristics of patients were considered. NOD2/CARD15 genotyping, presence of bacterial-DNA, defensin and cathelicidin gene, and protein levels in neutrophils and serum cytokine levels were studied. Twenty patients (40%) presented bacterial-DNA in blood. Eleven were active and 9 were in remission. Bacterial-DNA was not present in controls. NOD2/CARD15 mutations were identified in 25 patients (50%), 15 of which were in remission. Sixty percent of bacterial-DNA(+) and 43% of bacterial-DNA(-) patients showed a NOD2/CARD15 mutation. β-Defensin 2 and LL-37 mRNA and protein levels were upregulated in bacterial-DNA(+) patients. β-Defensin 2 and LL-37 expression correlated with bacterial-DNA concentration only in patients with a wildtype NOD2/CARD15 genotype. Cultured neutrophils of bacterial-DNA(-) patients confirmed the muramyl dipeptide-independent association between DEFB2 and LL-37 with bacterial-DNA concentration in wildtype NOD2/CARD15 patients. Cytokine levels were increased in bacterial-DNA(+) patients and correlated with bacterial-DNA concentration. NOD2/CARD15 genotype did not influence this correlation. β-Defensin 2, LL-37, and proinflammatory cytokines are increased in CD patients with bacterial-DNA in a concentration-dependent manner. NOD2/CARD15 plays a key role in the regulation of this response.

Study Information

Provider

pubmed

Year

2010

Date

2010-11-15T00:00:00.000Z

DOI

10.1002/ibd.21537

Citations

53

References

50